About ReCode Therapeutics
ReCode Therapeutics is a Healthcare company based in Menlo Park (United States) founded in 2015 by Daniel J Siegwart and Philip Thomas. Precision medicines for lung-related diseases are developed. ReCode Therapeutics has raised $371 million across 8 funding rounds from investors including Amgen, Pfizer and Orbimed. ReCode Therapeutics was last valued at $372 million in October 2021. Its chief executive, as recorded, is Shehnaaz Suliman. ReCode Therapeutics offers products and services including SORT LNP Platform and Therapeutics Pipeline. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its legal entity is RECODE THERAPEUTICS, INC. Its competitors include aTyr Pharma, InterMune and GEn1E; 2 of its 3 listed competitors have raised funding.
Company details
ReCode Therapeutics was founded in 2015 and is based in Menlo Park, United States. Precision medicines targeting lung-related diseases are developed, with a focus on the biotech sector. The pipeline features programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. A proprietary non-viral lipid nanoparticle platform is employed to deliver nucleic acid and protein payloads, enabling organ-specific targeting through systemic and local administration routes.
- Headquarters Menlo Park, United States
- Founders Daniel J Siegwart, Philip Thomas
- Stage Minicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website recodetx.com
- Social LinkedIn X Instagram
- Legal Name Recode Therapeutics, Inc.
- Total Equity Funding$371M (USD)
in 8 rounds
- InvestorsAmgen
& 18 more
Products & Services of ReCode Therapeutics
ReCode Therapeutics offers a comprehensive portfolio of products and services, including SORT LNP Platform and Therapeutics Pipeline.
Enables targeted delivery of genetic medicines to specific organs
Develops mRNA and gene correction therapies for rare diseases
Funding Insights of ReCode Therapeutics
ReCode Therapeutics has successfully raised a total of $371M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $371M
- Total Rounds 8
- First Round $2M
(Feb 2019)
- Investors Count 19
All 8 funding rounds of ReCode Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | Series B | – | – | ||
| Sep 2025 | $29M | Series B | – | – | |
| Sep 2023 | $50M | Series B | – | Solasta Ventures, Bioluminescence Ventures | |
| Jan 2023 | $10M | Series B | – | Cystic Fibrosis Foundation | – |
| Jun 2022 | $120M | Series B | – | Leaps by Bayer, AyurMaya | |
| Oct 2021 | $80M | Series B | $372M | Sanofi Ventures | |
| Mar 2020 | $80M | Series A | – | – | |
| Feb 2019 | $2M | Seed | – | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Oct 2021 | $372M | •••••••• |
Last known valuation $372M (Oct 2021). 19 investors in total: 19 institutional.
Investors in ReCode Therapeutics
ReCode Therapeutics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Pfizer and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare startups | solasta-ventures.com | Boston, United States | ||
A venture capital firm focused on biotechnology innovations. | bioluminescence.com | San Francisco, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Venture capital firm focused on therapeutics drugs | timefoliocapital.co.kr | Seoul, South Korea | ||
Private equity investments are managed by this USA-based firm. | coltventures.com | Dallas, United States |
Investor details for ReCode Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReCode Therapeutics
49 people are tracked at ReCode Therapeutics (15 in leadership, 12 in board & advisors, 22 in team).
| Name | Role | Group |
|---|---|---|
Daniel J Siegwart | Co-Founder | Leadership |
Philip Thomas | Co-Founder | Leadership |
Shehnaaz Suliman | CEO | Leadership |
Joseph Chen | Director, Translational Sciences | Leadership |
Karpagam Srinivasan | Director, CNS Delivery And Genomics | Leadership |
David J Lockhart | President & Chief Scientific Officer | Leadership |
Sakya Mohapatra | Senior Director, Formulation and Process Development | Leadership |
Diana Dong | Director, Clinical Project Management | Leadership |
Ariel Kantor | Vice President, Business Development & Platform Strategy | Leadership |
Marina Matkova Ristov | Director, Contracts | Leadership |
Stacy Sherman | Senior Director, Program Management | Leadership |
Joe Cefalu | Senior Director of In Vivo Pharmacology | Leadership |
Laura Kahn | Vice President R&d Strategy And Operations | Leadership |
Anna MARTINEZ | Senior Director / Site Head | Leadership |
Arunan Kaliyaperumal | VP, Preclinical Biology | Leadership |
Alan Colowick | Director | Board & advisors |
Helen S. Kim | Director | Board & advisors |
Peter Thompson | Director | Board & advisors |
Ed Hurwitz | Director | Board & advisors |
Oleg Nodelman | Director | Board & advisors |
29 more people are available in the full profile.
Complete people profiles for ReCode Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReCode Therapeutics
4 dated milestones of ReCode Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded ReCode Therapeutics is founded.
- Funding First funding round of $2.0M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B,.
Competitors of ReCode Therapeutics
ReCode Therapeutics has 3 listed competitors in our database, 2 of them funded. They include aTyr Pharma, InterMune and GEn1E.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. | |
| intermune.com | 1998 | Brisbane, United States | 359 | Therapies in pulmonology and orphan fibrotic diseases. | ||
| gen1e.com | 2018 | Palo Alto, United States | $17.15M | Developer of therapeutics for the treatment of inflammatory and rare diseases |
Detailed competitors of ReCode Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReCode Therapeutics
The website of ReCode Therapeutics (recodetx.com) receives about 6.5K visits a month and ranks #3,686,380 among all websites worldwide, #4,729 in Biotechnology and Pharmaceuticals.
- Monthly visits6.5K
▲ 29.7% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,686,380
among all websites
- Category rank#4,729
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.8
- Average visit12 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with ReCode Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| apollohealthco.com | 100% | #862,279 | View details | ||
| recodesolutions.com | 54% | 1.5K | #9,296,053 | View details | |
shop.recodestudios.com | shop.recodestudios.com | 48% | #1,316,991 | – |
Top companies in Pulmonology
3 companies that operate in the same segment as ReCode Therapeutics (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recode Therapeutics
Complete news archive for ReCode Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReCode Therapeutics
ReCode Therapeutics was founded in 2015 and raised its 1st funding round 4 years after it was founded.
ReCode Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Shehnaaz Suliman is the CEO of ReCode Therapeutics, as recorded in our data.
ReCode Therapeutics is a funded company, having raised a total of $371M across 8 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Feb 2019.
ReCode Therapeutics was founded in 2015 and is based in Menlo Park, United States. Precision medicines targeting lung-related diseases are developed, with a focus on the biotech sector. The pipeline features programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. A proprietary non-viral lipid nanoparticle platform is employed to deliver nucleic acid and protein payloads, enabling organ-specific targeting through systemic and local administration routes.
ReCode Therapeutics's top competitors include aTyr Pharma, GEn1E and InterMune.
ReCode Therapeutics offers SORT LNP Platform and Therapeutics Pipeline.
ReCode Therapeutics has 19 investors. Key investors include Amgen, Pfizer, Orbimed, Cystic Fibrosis Foundation, and Tekla Capital Management.
The valuation of ReCode Therapeutics is $372M as of Oct 2021.
ReCode Therapeutics operates through Recode Therapeutics, Inc..